Io Products provides a unique investment opportunity for small investors - in a market that is anticipated to become substantial if not explosive in the next decade.

1. Confidential and Proprietary1
A Once-in-a-Lifetime Investment Opportunity
A Mission to Improve World Health & Intelligence

2. Confidential and Proprietary
Io Products Opportunity
• Io Products, Inc.: Patents/systems/methods for Pregnancy, Antisepsis, &
Adjunctive Pharmaceuticals for a broad range of conditions & diseases
• Focus: The deployment of iodine in various forms and delivery vehicles to
enhance and speed cures, sidestep numerous diseases, and generally improve
hospital, clinical and home healthcare outcomes.
• Sales/Service: Via insurance, practices, hospitals, SNFs, others
• Profits:
• Traditional: Patient care, and Procedures (Imaging, Labs-CLIA Certified)
• Telemedicine: Device Sales/Lease and Clinical Monitoring
• Growth: Phase I needs up to $4MM cash
• Opportunity: 13.3% of Company equity
• Valuation: $30M
1

3. Confidential and Proprietary
The Io Products, Inc. Mission
Io Products, Inc. Health is a Population Health
Management and Technology company, providing an
integrated platform of proprietary telemedicine
technology and leveraging patented software in data
processing for specialty chronic care management and
real-time care, resulting in improved patient outcomes
and reduced costs.
2

4. Confidential and Proprietary
The Io Products, Inc. Team - I
• Michael Shen, MD – Founder & Chief Medical Officer
MD Certificates & Fellowships (Yale, Jiamusi/China, Cleveland Clinic, Robert Wood Johnson)
Specialization in healthcare data processing, extraction and outcome management with patents
Substantial publications, chairmanships
• Michael Seltzer – Chief Executive Officer
CEO of Humana Florida (former)
30 years executive healthcare management for $6B corporate revenues
• Franco Lodato – Chief Design Officer
Chief Innovator Officer for DuPont and Motorola
72 patents in mobile devices, wearables, 1st mobile ECG
Award-winning Industrial Engineer
3

5. Confidential and Proprietary
The Io Products, Inc. Team - II
• Roger Hernandez – CTO
 Over 25 experience in large system design and implementation
 Lead Io Products, Inc. Health 5 years in System design/expansion/customization
• Eric Dandes – Senior Financial Analyst
 MS in Healthcare & Finance
 Financial, medical & sales channel modeling
• Eugene Rosov – Business Development Officer
 Harvard College
 Pres./CEO of 3 public entities
 Raised $14M NASDAQ entity SB-1
• J. Everett Wilson, Esq. – Healthcare Attorney
 Partner, Akerman LLP, Miami FL – A premier healthcare, M&A and trial law firm
 J.D., University of Miami (cum laude); B.A., University of Florida (summa cum laude)
 Specialist: Medicare/Medicaid, regulatory compliance, provider ops, managed care
4

6. Confidential and Proprietary
Patients – Patents - Practices - Profits
• Patients: U.S. has inadequate resources for measuring & monitoring patients.
No care integration. Cost to hospitals, SNFs, PCPs is huge.
• Patents: Io Products, Inc.’s 3 patented programs
Gap Identification patients for better treatment/closer monitoring based on Guidelines
Chronic Disease Management: Care optimization/utilization for intervention
Acute Event Care: Customized device selection and 24/7 monitoring for immediate care
• Practices: U.S. practices cannot identify those in need – 31% of patients are
lost (& likely die) from cardiac events
• Profits: Federally-funded programs will continue (like dialysis) for 40+ years.
Monthly revenue to us: $500-$1,000 per patient
5

7. Confidential and Proprietary
Patients
• 2030: 40% of U.S. population will have Cardio-Vascular Disease
CVD is Io Products, Inc.’s initial Chronic Disease Management sector
Same sales channels & medical partners for future sectors
• COST: 3X Cost today - $272B to $818B
• CONTEXT: Total United States federal budget is $3.9T
• CVD TODAY: 7% of the total U.S. budget
• NEXT DUXLINK TARGETS: Diabetes, High Risk OB
6

8. Confidential and Proprietary
GDT-EMR Trial
Improve Patient Tx Compliance to Guidelines
7
• A Randomized & Prospective Clinical Trial (funded by BSC)
• Analysis of standard care on patients with CMP/CHF at CCF
• 1,911 consecutive patients in 2013
• 254 patients indicated for ICD or CRT
• 94 (37%) received ICD/CRT and 39 (15%) not indicated for ICD/CRT
• 98 (39%) deviated from standard care-actionable candidates
• 54 (55%) “seen a specialist but no firm plans for device implant”
• 22 (23%) “did not have any specialist referral for evaluation”
• 23 (9%) deceased within the year
• Based on international established databases, 43 lives could be saved with
improved quality of life as well as additional ~ $3.8 million hospital revenues.
Kozdag G, and Shen M: J Cardiac Failure, 2014

9. Confidential and Proprietary
Isolated Management – Today’s Care Status
No integrated care – No shared data or treatment plan
Io Products, Inc. dramatically changes this scenario
8
Patients
Physicians
Devices
Pharmacy
CareFacilities
Insurance

10. Confidential and Proprietary
Io Products, Inc. Integration Services
9

11. Confidential and Proprietary
Patents
• Patented Systems and Methodology:
EMR Integration & Data Extraction: convert non-structured display-focused data/graphs
to structured data and analysis-focused data
Procedure Utilization: Identify diagnosis/treatment gaps using clinical data/CPT codes
Outcome Optimization: Improving Clinical and Financial Outcomes
• Further Developments: Application Patents under above System& Methodology Patents
Devices: different specialty, such as high risk OB
Systems: different software, such as pharmacy/supplement gap identification/guidance
Services Integration: device/management/service for VIP patients under CardiacLink24
10

12. Confidential and Proprietary
Practices
• Partners: Io Products, Inc. partners with hospitals, SNFs, PCPs, MSOs, ACOs,
LTACs, 3rd party payers, private patients worldwide. Partnerships:
 Catholic Hospital Systems: Trial leading to approx. 2,000 patients
 Aetna: Trial phase (pending approval) - 3,000-5,000 members
 Home Healthcare: Private practices’ medium-to-high risk patients
• Network: Io Products, Inc. tele-health monitoring network is unique – available to
PCPs, institutions, specialists, SNFs, LTACs
• Practice Value:
Provides actionable care for the gaps, improves outcomes with lower cost
More income Avenues: device lease, monitoring and cost saving shares
Provides revenue-sharing with Io Products, Inc. using its platforms
11

13. Confidential and Proprietary
Profits
• Patient Tracking: $500-$1,000/month/pt.
• Patient Discovery: $1,000 to $5,000/pt.
Based on the institution’s savings & billing
• Current pretax projections by year:
FY 2016: -$ 2,300,000
FY 2017: -$ 1,700,000
FY 2018: +$ 8,800,000
FY 2019: +$ 41,300,000
FY 2020: +$111,700,000
12

14. Confidential and Proprietary
Investment Form & Value
• Valuation (Patents + Business Models + Clients + Prospects): $30,000,000
• Cash Requirement: $ 4,000,000
• Investment Format: Convertible Debenture
Issuer: Io Products, Inc. Health, Inc.
Share Price: 25% less than most recent offering or by outside valuation
Coupon Rate: 8.00% - Maturity Date: June 30, 2019
Conversion Terms: Each $1,000,000 debenture is convertible into common shares
at the lender’s option after June 30, 2017 and before June 30, 2019
Call Feature: Io Products, Inc. may call them anytime after June 30, 2019 at
$1,000,000 (plus accrued interest)
Acquisition/Public Offering: Share price at 50% of street offering
• Potential Investor Benefit: 200%-500% or more
13

15. Confidential and Proprietary
Summary
• Io Products, Inc. is totally unique in every way
Powerful, secure, proven patents
Current clients with large growth opportunity
Operations, reimbursement, shared/saved revenue
Improves patient outcomes
Reduces healthcare expenses
Effective proven team of dedicated professionals
• Io Products, Inc. is a once-in-a-lifetime investment
14